Drugs News and Research

RSS

$Type 2 diabetes drug may be used to treat heart failure with preserved ejection fraction$

Type 2 diabetes drug may be used to treat heart failure with preserved ejection fraction

Researchers at the University of Arizona have discovered that metformin, a drug commonly used to treat type 2 diabetes, might also be used to treat heart failure with preserved ejection fraction, a condition that is predicted to affect over 8% of people ages 65 or older by the year 2020.

19 Dec 2018

MUSC researchers identify potential therapeutic target for lung fibrosis

In an article published online by Frontiers in Endocrinology, researchers at the Medical University of South Carolina report that they have identified a potential therapeutic target for lung fibrosis or scarring.

19 Dec 2018

Vaping surges among American teenagers says new report

A latest report finds that United States teenagers are increasingly using e-cigarettes also known as vapes. These electronic cigarettes were initially targeted towards adults who were willing to quit smoking.

19 Dec 2018

GABA cells help fight alcohol dependence, study finds

Scientists of the Higher School of Economics, Indiana University, and École normale supérieure clarified how alcohol influences the dopamine and inhibitory cells in the midbrain that are involved in the reward system and the formation of dependency on addictive drugs.

19 Dec 2018

Hep C and drug abuse often go hand in hand, but screening for infection lags

When people seek help at a drug treatment center for an opioid addiction, concerns about having contracted hepatitis C are generally low on their list.

19 Dec 2018

HPV discovery could lead to new treatments for cervical cancer

Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus that could lead to new treatments for cervical cancer and other cancers caused by the virus.

19 Dec 2018

Horizon Discovery partners with C4XD to validate novel synthetic lethal oncology targets

Horizon Discovery Group today announces that it has entered into an exclusive target discovery partnership with C4XD, a pioneering drug discovery company.

From Revvity 19 Dec 2018

Developing the Next Generation of Water-soluble DREADDs

An interview with James Flanaghan, discussing the uses of DREADDs in neurobiological research and the advantages of water-soluble ligands.

From Hello Bio 19 Dec 2018

Researchers aim to improve cognition, reverse weight gain in schizophrenia

Aerobic exercise can improve the size and function of the brain, and now investigators want to know if it can also improve cognitive function in patients with schizophrenia who struggle with memory and attention problems.

19 Dec 2018

Hepatitis C drug can eliminate chikungunya, yellow fever virus

A study performed at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.

19 Dec 2018

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

Study finds high prevalence of TB infection among Tibetan refugee schoolchildren

In a tuberculosis screening and treatment initiative covering the entire population of Tibetan refugee schoolchildren in northern India, a team directed by researchers at Johns Hopkins Medicine and the University of Wisconsin says it has found not only a startlingly high prevalence of TB disease and infection, but also a potentially workable strategy to eliminate the disease in a large, high-risk group.

19 Dec 2018

Study may identify new diagnostics and treatment option for CVD

Forty-two percent of all deaths in the United States are related to cardiovascular disease. According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone.

19 Dec 2018

New drug could significantly slow progression of ALS, shows research

A new drug could significantly slow the progression of ALS, also known as Lou Gehrig's disease, according to new research by University of Alberta biologists. Current treatments slow progression of the degenerative disease by only a few months, and these findings could revolutionize the treatment of patients suffering from ALS, extending and improving quality of life.

18 Dec 2018

FSU researchers discover how breast cancer evades immune system detection

Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team of FSU researchers is now a little bit closer to figuring out why.

18 Dec 2018

New therapy for childhood blindness shows 'very promising' results

A new therapy aimed at improving the sight of people with one of the most common forms of childhood blindness, has shown 'very promising' initial results, according to a study involving UCL researchers.

18 Dec 2018

Combination of a vaccine and checkpoint drugs reduces pancreatic tumors in mice

Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people with pancreatic cancers whose response to standard immunotherapy is poor.

18 Dec 2018

New compound blocks genetic cause of familial ALS and frontotemporal dementia

Since the ice bucket challenge went viral in 2014, raising awareness and funding for ALS research, scientists have learned much about a disease that disconnects muscles from nerves, leading to muscle atrophy and eventual death. Their ultimate goal is to create medications capable of stopping ALS in its tracks.

18 Dec 2018

Study reveals mechanism behind failed remyelination in MS

Researchers have discovered that in adult stem cells, the activation of a specific transcription factor induces pathological quiescence and that this is deactivated in MS.

18 Dec 2018